6.42
0.28 (4.56%)
| Penutupan Terdahulu | 6.14 |
| Buka | 6.07 |
| Jumlah Dagangan | 85,576 |
| Purata Dagangan (3B) | 94,132 |
| Modal Pasaran | 54,030,720 |
| Harga / Jualan (P/S) | 0.250 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 May 2025 - 12 May 2025 |
| Margin Keuntungan | -52.62% |
| Margin Operasi (TTM) | -102.42% |
| EPS Cair (TTM) | -13.95 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -9.50% |
| Nisbah Semasa (MRQ) | 1.70 |
| Aliran Tunai Operasi (OCF TTM) | -127.49 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -77.12 M |
| Pulangan Atas Aset (ROA TTM) | -36.88% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Karyopharm Therapeutics Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.20 |
|
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 6.86% |
| % Dimiliki oleh Institusi | 48.43% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 42.00 (Baird, 554.21%) | Beli |
| Median | 33.00 (414.02%) | |
| Rendah | 10.00 (Barclays, 55.76%) | Beli |
| Purata | 28.33 (341.28%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 4.92 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Baird | 13 May 2025 | 42.00 (554.21%) | Beli | 4.92 |
| 03 Mar 2025 | 54.00 (741.12%) | Beli | 7.25 | |
| Barclays | 13 May 2025 | 10.00 (55.76%) | Beli | 4.92 |
| RBC Capital | 13 May 2025 | 33.00 (414.02%) | Beli | 4.92 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |